<?xml version="1.0" encoding="UTF-8"?>
<front-stub>
 <article-id pub-id-type="doi">10.5256/f1000research.18057.r40107</article-id>
 <title-group>
  <article-title>Reviewer response for version 1</article-title>
 </title-group>
 <contrib-group>
  <contrib contrib-type="author">
   <name>
    <surname>Voss</surname>
    <given-names>Gerald</given-names>
   </name>
   <xref ref-type="aff" rid="r40107a1">1</xref>
   <xref ref-type="aff" rid="r40107a2">2</xref>
   <role>Referee</role>
   <contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1984-5121</contrib-id>
  </contrib>
  <aff id="r40107a1">
   <label>1</label>SciPeo Sprl, Lelystad, Belgium
  </aff>
  <aff id="r40107a2">
   <label>2</label>Tuberculosis Vaccine Initiative (TBVI), Lelystad, The Netherlands
  </aff>
 </contrib-group>
 <author-notes>
  <fn fn-type="COI-statement">
   <p>
    <bold>Competing interests: </bold>No competing interests were disclosed.
   </p>
  </fn>
 </author-notes>
 <pub-date pub-type="epub">
  <day>26</day>
  <month>11</month>
  <year>2018</year>
 </pub-date>
 <related-article related-article-type="peer-reviewed-article" id="d35e10340" ext-link-type="doi" xlink:href="10.12688/f1000research.16521.1" xmlns:xlink="http://www.w3.org/1999/xlink">Version 1</related-article>
 <custom-meta-group>
  <custom-meta>
   <meta-name>recommendation</meta-name>
   <meta-value>approve</meta-value>
  </custom-meta>
 </custom-meta-group>
</front-stub>
